Sponsor study identifier
observational
30
1 country
1
Study Start
August 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
November 2007
Actual (reported)The purpose of this study is to examine the outcomes of those who have received Daclizumab as part of their immuno-suppression protocol following heart transplantation. Literature suggests that the time to first rejection episode can be avoided or delayed by using induction therapy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2007
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2004
Date type not reportedThis date has not been verified as actual or estimated.
June 12, 2007
Actual (reported)June 13, 2007
Actual (reported)November 2007
Actual (reported)Status post heart transplant Age 0-21 years Received Daclizumab as induction therapy
Contact the study team to confirm eligibility.
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
Kirk R Kanter, MD
Children's Healthcare of Atlanta, Pediatric Surgery
30 participants (actual enrollment reported by the registry).
First Submitted
June 12, 2007
First Posted
June 13, 2007
Study Start
August 2004
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
November 2007
Actual (reported)Last Updated
November 21, 2011
Record last verified: 2007-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: